ESPERION THERAPEUTICS, INC.
ESPR · NASDAQ
Through scientific and clinical excellence, and a deep understanding of cholesterol biology, the experienced Lipid Management Team at Esperion is committed to developing new LDL-C lowering medicines that will make a substantial impact on reducing global cardiovascular disease, the leading cause of death around the world.
ESG Scores
Overall ESG3.2
Environmental2.4
Social2.2
Governance5.6
Gender Diversity
Female Directors0.2%
CEO GenderMale
Market Data
Price$2.02-0.02 (-0.98%)
Market Cap$510M
P/E Ratio—
EPS$—
52W High$4.18
52W Low$0.69
Beta0.98